{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:31Z","timestamp":1764510391560},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T00:00:00Z","timestamp":1287360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T00:00:00Z","timestamp":1287360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/bmt.2010.239","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T14:56:47Z","timestamp":1287413807000},"page":"976-980","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis"],"prefix":"10.1038","volume":"46","author":[{"given":"K","family":"Quillen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Seldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K T","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,18]]},"reference":[{"key":"BFbmt2010239_CR1","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2009-04-202879","volume":"114","author":"RL Comenzo","year":"2009","unstructured":"Comenzo RL . How I treat amyloidosis. Blood 2009; 114: 3147\u20133157.","journal-title":"Blood"},{"key":"BFbmt2010239_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85\u201393.","journal-title":"Ann Intern Med"},{"key":"BFbmt2010239_CR3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","volume":"104","author":"DC Seldin","year":"2004","unstructured":"Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888\u20131893.","journal-title":"Blood"},{"key":"BFbmt2010239_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319\u2013328.","journal-title":"Am J Hematol"},{"key":"BFbmt2010239_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/bmt.2009.94","volume":"45","author":"M Rosenzweig","year":"2010","unstructured":"Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B et al. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a \u2018melphalan recall\u2019 reaction. Bone Marrow Transplant 2010; 45: 21\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010239_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.bmt.1705746","volume":"40","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007; 40: 557\u2013562.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010239_CR7","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","volume":"95","author":"R Desikan","year":"2000","unstructured":"Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008\u20134010.","journal-title":"Blood"},{"key":"BFbmt2010239_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","volume":"135","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Brit J Haematol 2006; 135: 158\u2013164.","journal-title":"Brit J Haematol"},{"key":"BFbmt2010239_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","volume":"28","author":"B Barlogie","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010; 28: 1209\u20131214.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010239_CR10","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/leu.2009.179","volume":"23","author":"JP Laubach","year":"2009","unstructured":"Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222\u20132232.","journal-title":"Leukemia"},{"key":"BFbmt2010239_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","volume":"3","author":"DC Seldin","year":"2003","unstructured":"Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241\u2013246.","journal-title":"Clin Lymphoma"},{"key":"BFbmt2010239_CR12","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","volume":"105","author":"G Palladini","year":"2005","unstructured":"Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949\u20132951.","journal-title":"Blood"},{"key":"BFbmt2010239_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","volume":"109","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492\u2013496.","journal-title":"Blood"},{"key":"BFbmt2010239_CR14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","volume":"114","author":"DE Reece","year":"2009","unstructured":"Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489\u20131497.","journal-title":"Blood"},{"key":"BFbmt2010239_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031\u20131037.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010239_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ajh.2830360217","volume":"36","author":"CD Hillyer","year":"1991","unstructured":"Hillyer CD, Comenzo RL, Miller KB, Schenkein DP, Tiegerman KO, Fogaren TA et al. Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. Am J Hematol 1991; 36: 152\u2013153.","journal-title":"Am J Hematol"},{"key":"BFbmt2010239_CR17","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1046\/j.1523-1755.2003.00936.x","volume":"63","author":"A Fadia","year":"2003","unstructured":"Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int 2003; 63: 1868\u20131873.","journal-title":"Kidney Int"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:26:57Z","timestamp":1648042017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,18]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFbmt2010239"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.239","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,18]]},"assertion":[{"value":"16 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}